CTLA4 and melanoma: Likewise, the higher expression levels of the IFN-γ-responsive genes appears to be vital for the clinical success of anti–CTLA-4 mAb as evidenced by the analysis of tumor specimens from melanoma patients treated with ipilimumab (Mo et al., 2018).